Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life

References

• Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002;21: 629-632
   PubMed Web of Science ®Google Scholar
• Katz BZ, Lo J, Sorrentino M. Costs of respiratory syncytial virus infection at a tertiary-care children's care hospital. Pharmacol Ther 2003;28:343-345
   Google Scholar
• Wegner S, Vann JJ, Liu G, Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics 2004;114:1612-1619
   PubMed Web of Science ®Google Scholar
• Joffe S, Ray GT, Escobar GJ, Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419-427
   PubMed Web of Science ®Google Scholar
• Paramore LC, Ciuryla V, Ciesla G, Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004;22:275-284
   PubMed Web of Science ®Google Scholar
• Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2007. Natl Vital Stat Rep 2009;57:1-23
   Google Scholar
• Engle WA, Tomashek KM, Wallman C. “Late-preterm” infants: a population at risk. Pediatrics 2007;120:1390-1401
   PubMed Web of Science ®Google Scholar
• Hoo AF, Dezateux C, Henschen M, Development of airway function in infancy after preterm delivery. J Pediatr 2002;141: 652-658
   PubMedGoogle Scholar
• Shapiro-Mendoza CK. Infants born late preterm: epidemiology, trends, and morbidity risk. Neoreviews 2009;10:e287-294
   Google Scholar
• Gilbert WM, Nesbitt TS, Danielsen B. The cost of prematurity: quantification by gestational age and birth weight. Obstet Gynecol 2003;102:488-492
   PubMed Web of Science ®Google Scholar
• McLaurin KK, Hall CB, Jackson EA, Persistence of morbidity and cost differences between late-preterm and term infants during the first year of life. Pediatrics 2009;123:653-659
   PubMed Web of Science ®Google Scholar
• Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003;143:S133-141
   PubMed Web of Science ®Google Scholar
• HIPAA privacy rule and public health. Guidance from CDC and the U.S. Department of Health and Human Services. MMWR Morb Mortal Wkly Rep 2003;52(Suppl):1-17, 19-20
   PubMedGoogle Scholar
• Department of Health and Human Services. Code of Federal Regulations. Title 45 – Public Welfare. Part 46 Protection of Human Subjects. Subpart A – Basic HHS Policy for Protection of Human Research Subjects. Available at: http://www.hhs.gov/ohrp/documents/OHRPRegulations.pdf. Accessed June 5, 2009
   Google Scholar
• Institute of Medicine. Preterm birth: Causes, consequences, and prevention. Washington, DC: National Academic Press, 2006
   Google Scholar
• Stewart DL, Romero JR, Buysman EK, Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention. Curr Med Res Opin 2009;25:2795-2804
   PubMed Web of Science ®Google Scholar
• Willson DF, Landrigan CP, Horn SD, Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003;143:S142-149
   PubMed Web of Science ®Google Scholar
• Atkins JT, Karimi P, Morris BH, Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost. Pediatr Infect Dis J 2000;19:138-143
   PubMedGoogle Scholar
• Elhassan NO, Sorbero ME, Hall CB, Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006;160:1070-1076
   PubMed Web of Science ®Google Scholar
• Hay JW, Ernst RL, Meissner HC. Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am J Manag Care 1996;2:851-861
   Google Scholar
• Lofland JH, O'Connor JP, Chatterton ML, Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000;22:1357-1369
   PubMed Web of Science ®Google Scholar
• Meissner HC. Economic impact of viral respiratory disease in children. J Pediatr 1994;124:S17-21
   PubMed Web of Science ®Google Scholar
• Meissner HC, Fulton DR, Groothuis JR, Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993;37:1655-1658
   PubMed Web of Science ®Google Scholar
• Stang P, Brandenburg N, Carter B. The economic burden of respiratory syncytial virus-associated bronchiolitis hospitalizations. Arch Pediatr Adolesc Med 2001;155:95-96
   PubMed Web of Science ®Google Scholar
• Altman CA, Englund JA, Demmler G, Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-438
   PubMed Web of Science ®Google Scholar
• Howard TS, Hoffman LH, Stang PE, Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality. J Pediatr 2000;137:227-232
   PubMed Web of Science ®Google Scholar
• Marchetti A, Lau H, Magar R, Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther 1999;21:752-766
   PubMedGoogle Scholar
• Underwood MA, Danielsen B, Gilbert WM. Cost, causes and rates of rehospitalization of preterm infants. J Perinatol 2007;27:614-619
   PubMed Web of Science ®Google Scholar
• Oelberg D, Reininger M, Van Eeckhout J. A cost-benefit analysis of respiratory syncytial virus hyperimmune globulin (RSV-IVIG) in high-risk infants. Neonatal Intensive Care 1998;11:29-33
   Google Scholar
• Leader S, Yang H, DeVincenzo J, Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants. Value Health 2003;6:100-106
   PubMed Web of Science ®Google Scholar
• Banerji A, Lanctot KL, Paes BA, Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr Infect Dis J 2009;28:702-706
   PubMed Web of Science ®Google Scholar
• Chan PW, Abdel-Latif ME. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. Acta Paediatr 2003;92:481-485
   PubMed Web of Science ®Google Scholar
• Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003;88:1065-1069
   PubMed Web of Science ®Google Scholar
• Farina D, Rodriguez SP, Bauer G, Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr Infect Dis J 2002;21:287-291
   PubMed Web of Science ®Google Scholar
• Greenough A, Cox S, Alexander J, Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85: 463-468
   PubMed Web of Science ®Google Scholar
• Lanctot KL, Masoud ST, Paes BA, The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008;24:3223-3237
   PubMed Web of Science ®Google Scholar
• Langley JM, LeBlanc JC, Wang EE, Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada Study. Pediatrics 1997;100:943-946
   PubMed Web of Science ®Google Scholar
• Liese JG, Grill E, Fischer B, Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:230-236
   PubMed Web of Science ®Google Scholar
• Miedema CJ, Kors AW, Tjon ATWE, Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands. Pediatr Infect Dis J 2001;20:160-163
   PubMed Web of Science ®Google Scholar
• Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. J Med Econ 2009;12:301-308
   PubMedGoogle Scholar
• Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health 2000;36:422-427
   PubMedGoogle Scholar
• Reeve CA, Whitehall JS, Buettner PG, Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006;42:253-258
   PubMed Web of Science ®Google Scholar
• Rietveld E, Vergouwe Y, Steyerberg EW, Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule. Pediatr Infect Dis J 2006;25:201-207
   PubMed Web of Science ®Google Scholar
• Roeckl-Wiedmann I, Liese JG, Grill E, Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:237-244
   PubMed Web of Science ®Google Scholar
• Tam DY, Banerji A, Paes BA, The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ 2009;12:361-370
   PubMedGoogle Scholar
• Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126:212-219
   PubMed Web of Science ®Google Scholar